Risperidone的問題，透過圖書和論文來找解法和答案更準確安心。 我們找到下列問答集和懶人包總整理

用藥相關問題評估：藥師SOAP紀錄精選

為了解決Risperidone的問題，作者周月卿,張豫立 這樣論述：

　　本書彙集藥師臨床服務的精華，為國內首本臨床藥事服務病歷紀錄的參考書籍。藥師進行臨床服務後必須將服務內容詳細記錄於病歷，供所有照護團隊人員瞭解病人用藥相關問題及處置。在醫療照護體系中，最廣泛被使用的紀錄格式是SOAP，它是主觀資料 (Subjective)、客觀資料 (Objective)、評估 (Assessment) 和計畫 (Plan) 的英文字首縮寫，以病人的臨床問題為導向，針對每一個問題提出解決方式與追蹤事項，並簡潔清楚地記錄於病歷。本書精選百件藥師服務紀錄，以用藥相關問題為主軸，分類收納藥師實際執行臨床服務時所記錄的SOAP，並於每篇SOAP後簡介疾病、藥品及

案例狀況，亦說明藥師進行用藥評估時的整體考量、提出的建議及後續追蹤，最後提供實證文獻。期盼本書的出版可以分享及傳承臨床藥事服務之專業知識技能，提供醫藥各界參閱與應用，不斷學習精進、共同成長貢獻所學，確保病人用藥療效與安全。

Risperidone進入發燒排行的影片

Drug-Drug Interaction Primer

為了解決Risperidone的問題，作者Sandson, Neil B., M.d./ Armstrong, Scott C., M.D. (CON)/ Cozza, 這樣論述：

This user-friendly resource offers complete and comprehensive coverage of the difficult challenges posed by drug-drug interactions. Over 170 case vignettes illustrate a variety of interactions (DDIs) to provide an unintimidating -- even entertaining -- approach to understanding these issues. Drug

-Drug Interaction Primer builds on the author's earlier work, Drug Interactions Casebook: The Cytochrome P450 System and Beyond, and features updated references throughout and 29 new cases that provide such clinical examples as: a patient diagnosed with schizoaffective disorder transitions from halo

peridol to aripiprazole with disastrous results; an AIDS patient's trimethoprim-sulfamethoxazole is replaced with warfarin following atrial fibrillation, resulting in ischemic stroke; and a delusional patient on risperidone is placed on phenytoin following seizures, and delusions return. Previous ca

ses have been revised to enhance clarity.An introduction to core concepts, which includes brief reviews of each enzyme system, brings the reader up to speed on how to think about DDIs and begin to grapple with what might seem like an imposing subject. The vignettes that follow each include a case pr

esentation and an explanation of the mechanism by which the interaction(s) occurred, and each derives from sound clinical evidence -- not merely extrapolations from drug characteristics -- to offer a more realistic understanding of DDIs. Most of the interactions described involve the cytochrome P450

enzyme system; others involve alterations in phase II metabolism and P-glycoprotein functioning, as well as plasma protein displacement effects. The appendices detail most drug-drug interactions between psychotropic agents and contain metabolic pathways and inhibitory and inductive profiles for ant

idepressants, antipsychotics, and mood stabilizing agents -- as well as tables that detail all known and clinically significant DDIs between pairings of any two agents from these drug classes. An extensive index allows quick reference. Among the book's other features: - Reorganization by medical sub

specialty -- psychiatry, internal medicine, neurology, surgery/anesthesia, and gynecology, oncology, and dermatology -- better facilitates clinical application.- Comprehensive tables detail substrates, inhibitors, and inducers for P450, phase II, and P-glycoprotein. - DDIs involving select nonpsycho

tropic agents such as tobacco, ethinylestradiol, and statins.- Exploration of the paradigm of plasma protein binding mediated DDIs in detail, with cases conveniently indexed. These cases bring DDIs alive in a way that drier descriptions cannot, and this volume introduces more original material than

will be found in other sources. Drug-Drug Interaction Primer is brimming with material that can be put to immediate use, offering insights that will improve any practitioner's skills.

Integrative genomic network-based drug repositioning for allergic diseases

為了解決Risperidone的問題，作者WIRAWAN ADIKUSUMA 這樣論述：

AbstractAllergy diseases are currently not totally cured, but treatment could reduce the symptoms and progress over time in many cases. Unfortunately, drug choice is limited, posing substantial challenges for drug discovery or utilizing the old drug for a new disease called repurposing drugs. Findi

ng a novel drug involves a lot of time, money, and effort. In addition to the high expense, the chances of a promising candidate compound becoming a US FDA-approved drug are low. Drug repositioning/repurposing is a method used to extend the effects of approved drugs or revitalize those that have fai

led, which will resolve these obstacles and problems. This thesis focuses on discovering potential treatments for allergy diseases based on an approach that integrates gene networks and genomics. Three diseases (atopic dermatitis (AD), asthma, and allergic contact dermatitis (ACD)) were included in

the study.In the first study, we investigated discover potential drugs repurposed for AD. Herein, the AD-associated SNPs were obtained from the GWAS catalog. We identified 70 AD risk loci, and 94 genes were found by extending the AD risk loci using HaploReg version 4.1 for Asian populations with r2

> 0.8. The scoring system was developed using six functional annotations to predict drug candidates optimally using in silico pipelines. Twenty-seven biological AD risk genes were identified and then mapped into 76 drug target genes using the STRING database. We identified 25 drug target genes that

overlap 53 drugs in DrugBank and Therapeutic Target Database. Interestingly, dupilumab was successfully found in this bioinformatics analysis of the 53 drugs. Dupilumab was known as one of the drugs available used for AD. This finding confirms the feasibility and reliability of gene-based drug repur

posing. Furthermore, ten drugs were identified with clinical or preclinical evidence that could be useful in AD. Specifically, we identified filgotinib and fedratinib with target JAK1 inhibitors that might be repurposed to AD because JAK1 is an essential potential target for AD.In the second study,

we conducted drug repositioning for asthma. This study used the GWAS and PheWAS databases to obtain asthma risk SNPs that could yield information that might help guide to drug repurposing process. We used five biological criteria to prioritize asthma-associated genes and develop biological risk cand

idates for drug repositioning. Our research identified 139 biological asthma risk genes and 64 drugs that target 22 of these genes. Noteworthy, reslizumab, mepolizumab, theophylline, dyphylline, aminophylline, oxtriphylline, and enprofylline are seven of 64 drugs successfully identified in this bioi

nformatic analysis as clinical use for asthma. In addition, we observed in a ClinicalTrial.gov and an intensive PubMed literature review 17 drugs in a clinical trial and preclinical study potentially useful for asthma. Additionally, 11 out of 40 candidate drugs were potential candidates to treat ast

hma. Notably, IL6R would be an ideal target for repurposing asthma drugs due to its high target scores. We found sarilumab and satralizumab to be the most potential candidate drugs for asthma using in silico drug repurposing.In the third study, we conducted our data mining analysis for drug targets

of ACD by integrating the differentially expressed genes (DEGs). We identified 370 DEGs, including 281 upregulated and 79 down-regulated genes. A GO and KEGG pathway were analyzed to determine the biological functions of genes and pathways involved in ACD. Then, using protein-protein interaction an

alysis, we clustered these genes and discovered 10 Hub genes that are deemed significant in our model. Additionally, we used the drug-gene interaction database to conduct a drug-gene interaction analysis of module genes. We discovered 14 drugs that might be used to prevent and cure ACD. Noteworthy,

among 14 drugs, two drugs are currently under clinical trials and three are off-label used for ACD. In addition, four anticancer drugs were identified as promising ACD therapy. However, due to the high risk of side effects, anticancer drugs were not considered for ACD drug repurposing in our study.

Through a transcriptomic-driven drug discovery approach, we identified five drugs (risperidone, diclofenac, loratadine, collagenase clostridium histolyticum, and ocriplasmin) as the most promising drug to be repositioned in ACD therapy.Overall, this study has provided the most promising candidate dr

ugs that have not been reported as anti-allergic and offer a valuable drug repurposing approach to provide empirical evidence for drug discovery of allergic diseases.Keywords: Atopic dermatitis, asthma, allergic contact dermatitis, bioinformatics, drug repurposing, functional annotations, genomic, t

ranscriptomic.